Epileptic medications and improving patient outcomes

https://doi.org/10.53730/ijhs.v8nS1.15084

Authors

  • Hamza Alsamannoudi KSA, KAMC-Riyadh
  • Abdulaziz Alamri KSA, KAMC-Riyadh
  • Ahmad Bawazeer KSA, KAMC-Riyadh
  • Tariq Almotiri KSA, KAMC-Riyadh
  • Sattam Alharbi KSA, KAMC-Riyadh
  • Delyal Alshammari KSA, KAMC-Riyadh
  • Bader Alnasser KSA, KAMC-Riyadh
  • Hani Alswayeh KSA, KAMC-Riyadh
  • Sari Alrasheedi KSA, KAMC-Riyadh

Keywords:

Epilepsy, Epileptic medications, neurological disorder

Abstract

Epilepsy is a chronic neurological disorder characterized by recurrent seizures, which are sudden and uncontrolled electrical disturbances in the brain. It is one of the most common neurological conditions, affecting approximately 50 million people worldwide (World Health Organization, 2019). Effective management of epilepsy is crucial, as uncontrolled seizures can lead to significant physical, psychological, and social consequences. The treatment of epilepsy primarily involves the use of antiepileptic drugs (AEDs), also known as anticonvulsants. These medications work by modulating the electrical activity in the brain, thereby reducing the occurrence and severity of seizures. Over the past several decades, research has focused on understanding the mechanisms of action, efficacy, and safety of various AEDs, as well as the factors that influence their clinical use. This study aims to provide a comprehensive review of the research literature on epileptic medications, covering key aspects such as: 1) The pharmacological mechanisms of action of AEDs; 2) The efficacy and safety profiles of established and newer AEDs; 3) Factors influencing the selection and use of AEDs, including patient characteristics, comorbidities, and drug interactions; 4) Emerging trends and future directions in the development and utilization of epileptic medications. 

Downloads

Download data is not yet available.

References

Brivaracetam Prescribing Information. (2022). UCB Pharma, Inc.

Keppra Prescribing Information. (2022). UCB Pharma, Inc.

Kwan, P., & Brodie, M. J. (2000). Early identification of refractory epilepsy. New England Journal of Medicine, 342(5), 314-319. DOI: https://doi.org/10.1056/NEJM200002033420503

Lacosamide Prescribing Information. (2022). UCB Pharma, Inc.

Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., ... & Tudur-Smith, C. (2007). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. The Lancet, 369(9566), 1000-1015. DOI: https://doi.org/10.1016/S0140-6736(07)60460-7

Perampanel Prescribing Information. (2022). Eisai Inc.

World Health Organization. (2019). Epilepsy.

Published

28-05-2024

How to Cite

Alsamannoudi, H., Alamri, A., Bawazeer, A., Almotiri, T., Alharbi, S., Alshammari, D., Alnasser, B., Alswayeh, H., & Alrasheedi, S. (2024). Epileptic medications and improving patient outcomes. International Journal of Health Sciences, 8(S1), 1073–1079. https://doi.org/10.53730/ijhs.v8nS1.15084

Issue

Section

Peer Review Articles

Most read articles by the same author(s)